Omni Bio Pharmaceutical, Inc.

Omni Bio is revolutionizing the treatment of inflammatory disease. Our product has demonstrated superior potency, and greater half-life and mfg scalability.

  • Stage Product In Development
  • Industry Biotechnology
  • Location Fort Collins, CO, US
  • Currency USD
  • Founded 2005
  • Employees 2
  • Website omnibiopharma.com

Company Summary

Omni Bio Pharmaceutical, Inc. is an emerging biopharmaceutical company focused on revolutionizing the treatment of immune-mediated inflammatory disease. The Company’s technology platform, Fc-AAT, is a recombinant version of plasma-derived alpha-1 antitrypsin (p-AAT), a naturally occurring human protein that is currently commercialized as an intravenous supplementation therapy for AAT-deficient individuals.

Team

  • John Riccardi
    CFO

    Mr. Riccardi, has been CFO of Green Street Ventures, LLC, a private equity fund, since 2012. Prior to this, Mr. Riccardi worked for ADial Pharmaceuticals, LLC, a privately held pharmaceutical co developing medications for treating addiction disorders, where he served as CFO Treasurer and Secretary. Earlier in his career, Mr. Riccardi spent eight years at General Motors, last serving as Director, Strategic Planning.

  • Bruce Schneider
    CEO

    Dr. Schneider was employed by Pfizer as Executive Vice President & R&D Integration Lead. From 1972 to 2009, he was employed by Wyeth Research, where he held numerous senior R&D positions, including Executive VP & Chief of Operations, Senior VP, Research Operations & Planning and VP, Worldwide Clinical Operations. Dr. Schneider holds a Ph.D. in Applied Statistics from Temple Univ and a Sc.B in Applied Mathematics from Brown Univ.

Starting a startup?

Join the world's largest startup network for guidance, tools, and fundraising opportunities.

Get Started for Free